RE-BVS – Piemonte Repository

Sfoglia per AUTORE
NADAL E
Collezione AOU San Luigi di Orbassano

Items : 6

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032.

2024
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Aix SP; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Nishino K; Yoh K; Shih JY; Chik JYK; Moro-Sibilot D; Puri T; Chacko Varughese S; Frimodt-Moller B; Visseren-Grul C; Reck M;

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). in Cancer treatment reviews / Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31.

2022
AOU San Luigi di Orbassano

Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S; Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;

Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. in Translational lung cancer research / Transl Lung Cancer Res. 2021 Jul;10(7):3191-3202. doi: 10.21037/tlcr-21-455.

2021
AOU San Luigi di Orbassano

Zhang X; Tian D; Chen Y; Chen C; He LN; Zhou Y; Li H; Lin Z; Chen T; Wang Y; Russo A; Nadal E; Passiglia F; Soo RA; Watanabe S; Moran T; Oh IJ; Fu S; Hong S; Zhang L;

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19.

2021
AOU San Luigi di Orbassano

Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; et alii...

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. in Cancer treatment and research communications / Cancer Treat Res Commun. 2021;27:100378. doi: 10.1016/j.ctarc.2021.100378. Epub 2021 Apr 19.

2021
AOU San Luigi di Orbassano

Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.

2019
AOU San Luigi di Orbassano

Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;